Dudley Capital Management LLC Lowers Position in Pfizer Inc. (NYSE:PFE)

Dudley Capital Management LLC decreased its position in shares of Pfizer Inc. (NYSE:PFE) by 1.1% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 55,531 shares of the biopharmaceutical company’s stock after selling 637 shares during the period. Dudley Capital Management LLC’s holdings in Pfizer were worth $1,473,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. CoreFirst Bank & Trust purchased a new stake in Pfizer in the fourth quarter worth about $226,000. Barnett & Company Inc. boosted its position in shares of Pfizer by 4.3% in the 4th quarter. Barnett & Company Inc. now owns 222,898 shares of the biopharmaceutical company’s stock worth $5,913,000 after purchasing an additional 9,273 shares in the last quarter. Prudential Financial Inc. increased its position in Pfizer by 67.5% during the 4th quarter. Prudential Financial Inc. now owns 6,927,537 shares of the biopharmaceutical company’s stock valued at $183,788,000 after buying an additional 2,792,786 shares in the last quarter. Lynx Investment Advisory raised its stake in Pfizer by 14.2% during the fourth quarter. Lynx Investment Advisory now owns 31,161 shares of the biopharmaceutical company’s stock valued at $827,000 after buying an additional 3,866 shares during the last quarter. Finally, Woodmont Investment Counsel LLC boosted its holdings in Pfizer by 11.2% in the fourth quarter. Woodmont Investment Counsel LLC now owns 252,994 shares of the biopharmaceutical company’s stock worth $6,712,000 after acquiring an additional 25,505 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of PFE opened at $26.13 on Tuesday. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54. The business has a fifty day moving average of $26.15 and a 200 day moving average of $27.02. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The firm has a market capitalization of $148.21 billion, a P/E ratio of 18.53, a PEG ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. During the same quarter last year, the company posted $0.10 EPS. The company’s revenue was up 24.7% compared to the same quarter last year. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on PFE. Citigroup reduced their price target on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a report on Tuesday, January 28th. Truist Financial decreased their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. Guggenheim reiterated a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. Bank of America restated a “neutral” rating and issued a $29.00 price objective on shares of Pfizer in a report on Tuesday, December 10th. Finally, UBS Group cut their target price on Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $31.92.

Insiders Place Their Bets

In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of the company’s stock in a transaction dated Thursday, February 13th. The stock was purchased at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. The trade was a 235.84 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.06% of the company’s stock.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.